Background: Given the increasing prevalence of Inflammatory Bowel Diseases (IBD) in Brazil  and considering that the highest peak incidence occurs in young patients; the work disability generates relevant economic and social impacts. This study aimed at assessing disability due to IBD in the Brazilian population.
Methods: Analysis was obtained through the computerized Single System of Social Security Benefits Information with the crosscheck of aid pension and disability retirement, for ulcerative colitis (UC) and Crohn's disease (CD) between 2010 and 2014. Additional data were obtained within the platform including the average values, benefit duration, gender, age, and region of the country.
Results: In terms of costs, the value of benefits paid from 2010 to 2014 for IBD was US$ 98,098,212,representing approximately 1% of the total of all benefits paid by the social security. Benefits paid for CD were higher than for UC, whereas both tend to decrease from 2010 to 2014.
Temporary disability was more frequent in UC, while permanent disability in CD. Temporary disability affected younger patients with CD than UC. Rates for temporary and permanent disability were greater among women. Temporary work absences due to UC and CD were greater in the South, while the lowest rates in the North and Northeast, due to CD. Permanent disability rates were higher in the South (UC) and Southeast (CD). Absence from work was longer in CD (355 days) compared to UC (305 days), reaching almost a year.
Conclusions: IBD-related work disability rates are much longer in Brazil, compared to the ones seen in developed countries . Reduction trends may reflect improvements in access to health care and medication. Vocational rehabilitation programs may positively impact social security and quality of life of patients.
 Bassi A; Dodd S; Williamson P et al, (2004), Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study, GUT, 1471–1478, 53
 Van Deen WK, Esrailian E, Hommes DW, (2015), Value-based care for inflammatory bowel diseases, J Crohns Colites, J Crohns Colites, 421–427, 9(5)
 Rocchi A; Benchimol E; Bernstein C et al, (2012), Inflammatory bowel disease: A Canadian burden of illness review, Can J Gastroenterol, 811–818, 26(11)
 Ganz, ML, Surgarman R, Wang R, et al, (2016), The economic and health impact of of Crohn's disease in the United States: Evidence from a Nationally Representative Survey, Inflamm Bowel Dis, 1032–1040, 22(5)
 Kaplan, G.G., (2015), The global burden of IBD: from 2015 to 2025, Nat. Rev Gastroenterol. Hepatol, 720–727, 12
 Hoivik, M.L.; Moum, B.; Solberg, I.C et al. IBSEN Group, (2013), Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study, GUT, 368–375, 62
 Victoria, C.R.; Sasaak, L.Y.; Nunes, H.R, (2009), Incidence and prevalence rates od inflammatory bowel diseases, in Midwestern of São Paulo state in Brazil, Arq Gastroenterol, 20–25, 46
 Souza, M.H.L.P; Troncon, L.E; Rodrigues, C.M, et al, (2002), Evolução da ocorrência (1980–1999) da Doença de Crohn e da Retocolite Ulcerativa Idiopática e análise das suas características clínicas em um Hospital Universitário do Sudeste do Brasil, Arq Gastroenterol, 98–105, 39 (2)
 Kawalec P, Malinowski KP, (2015), Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis, Expert Rev Pharmacoecon Outcomes Res, 253–266, 15(2)
 Floyd DN, Langham S, Séverac HC et al, (2015), The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review, Dig Dis Sci, 299–312, 60(2)